People of color face higher risk of flu hospitalization as U.S. faces potentially severe season, CDC says

People of color face higher risk of flu hospitalization as U.S. faces potentially severe season, CDC says


People of color are hospitalized with the flu at far higher rates than white Americans, according to a large multi-year study from the Centers for Disease Control and Prevention.

The CDC study, published Tuesday, looked at flu hospitalizations among adults from 2009 through last year using data from its flu surveillance network that includes more than 70 counties across 14 states.

Hospitalizations were 80% higher among Black adults than white adults, 30% higher among Native Americans, and 20% among higher among Hispanics, according to the CDC data.

Vaccination rates were lower among people of color than white adults. During last year’s flu season, vaccination coverage among white adults was 54% compared with 38% among Hispanics, 41% among Native Americans and 42% among Black adults.

CDC officials, in a call with reporters Tuesday, said lower vaccination rates among people of color are due to poorer access to healthcare, distrust of physicians and the government due to historical discrimination, and missed opportunities to get people immunized when they do go to the doctor.

People of color also often face poorer and more crowded housing conditions and more chronic illnesses which makes hospitalization from the flu more likely, officials said.

Prior to the Covid-19 pandemic, influenza was one of the most challenging respiratory diseases that hospitals faced every year. Flu seasons vary in their severity depending on the strain of the virus and the efficacy of the vaccines. Over the past decade, 9 million to 41 million people fell ill every year, 140,000 to 170,000 individuals were hospitalized and 12,000 to 52,000 died annually, according to CDC data.

Carla Black, a CDC epidemiologist, told reporters on Tuesday that flu is difficult to forecast, but the U.S. could be facing one of the worst seasons since the Covid pandemic began more than two years ago.

“We’ve had two mild flu seasons and this means we might be ripe for a severe season because people aren’t taking all the measures they took for Covid which also had an impact on the flu,” Black said. “People haven’t had natural disease in two years so there’s less natural immunity out there.”

Only 49% of eligible adults got their flu vaccine last year. Black said everyone ages 6 months and older should get their shot, but the CDC views a flu vaccination rate of 70% as a success.

The effectiveness of flu shots varies from year to year, though they are usually 40% to 60% effective at preventing illness, Black said. “Even people who do get sick are less likely to have severe outcomes like hospitalization and death,” she said.

Dr. Ashish Jha, the White House Covid taskforce leader, has called for all Americans who are eligible to get both their Covid omicron booster as well as their flu shot as soon as possible.

“What happens in the weeks and months ahead will have a large impact on how the winter goes and really what happens this winter is largely up to us as the American people,” Jha told reporters last week.

“Don’t wait — get your new flu shot and your new Covid shot today. If Americans did that we could save hundreds of lives each day this winter,” he said.



Source

Danish weight loss drug maker outlines ambitious 2030 strategy, ramping up pressure on Novo, Lilly
Health

Danish weight loss drug maker outlines ambitious 2030 strategy, ramping up pressure on Novo, Lilly

Celsopupo | Istock | Getty Images Zealand Pharma on Thursday outlined an ambitious five-year strategy for its anti-obesity portfolio Thursday, spotlighting how growing competition from smaller players is tightening the race for market leaders Novo Nordisk and Eli Lilly as more of these medicines near market entry. The new strategy, “Metabolic Frontier 2030,” comes as Zealand […]

Read More
Eli Lilly to build  billion manufacturing plant in Alabama to help make upcoming obesity pill, other drugs
Health

Eli Lilly to build $6 billion manufacturing plant in Alabama to help make upcoming obesity pill, other drugs

Eli Lilly CEO David A. Ricks speaks at a press conference at Generation Park in Houston, Monday, Sept. 23, 2025. The company announced plans for a $6.5 billion biomanufacturing plant in north Houston. (Raquel Natalicchio/Houston Chronicle via Getty Images) Raquel Natalicchio | Houston Chronicle | Getty Images Eli Lilly on Tuesday said it will spend […]

Read More
A biotech stock for investors scared to invest in the risky industry
Health

A biotech stock for investors scared to invest in the risky industry

Citigroup thinks investors should consider Ligand Pharmaceuticals for a more conservative bet on the biotech industry. The bank initiated the biotech stock at a buy rating and price target of $270, implying upside of 46% from Ligand’s Monday closing price of $184.67. Shares have soared nearly 79% this year. LGND YTD mountain LGND YTD chart […]

Read More